Jonas Steenbrugge

6PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 03, 2025
The Poly (ADP-Ribose) Polymerase-1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study.

Shana De Vos, Simone Janssen, Sophie Favril

|Jul 28, 2022
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer.

Jonas Steenbrugge, Julie Bellemans, Niels Vander Elst

|Mar 18, 2021
OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer.

Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere

|Oct 01, 2020
Splenic Hematopoietic and Stromal Cells in Cancer Progression.

Jonas Steenbrugge, Emiel A De Jaeghere, Evelyne Meyer

|Aug 17, 2018
Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.

Jonas Steenbrugge, Koen Breyne, Kristel Demeyere

|Oct 08, 2016
Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer.

Jonas Steenbrugge, Koen Breyne, Sofie Denies

Pageof 1

Frequent Collaborators

1 joint publications

Emiel A De Jaeghere

1 joint publications

Olivier De Wever

1 joint publications

Niels Vander Elst

1 joint publications

Shana De Vos